1. Italy Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Recordati S.p.A.

Recordati S.p.A.

RCDTF
Recordati S.p.A.US flagOther OTC
58.00
USD
- -
- -
11.80BMarket Cap
Recordati S.p.A.
RCDTF
(Other OTC)

Recent

price

58.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.67
3.82
4.15
4.67
4.85
5.1
5.6
6.22
6.62
7.23
7.04
7.67
9.01
10.13
11.35
12.74
12.99
Revenue per Share
0.55
0.58
0.59
0.66
0.79
0.97
1.15
1.39
1.53
1.8
1.73
1.87
1.52
1.89
2.02
2.16
2.31
Basic EPS, GAAP
0.53
0.39
0.56
0.46
0.76
1.04
1.06
-0.23
1.75
-0.61
1.32
1.96
1.78
0.5
-1.36
2.49
2.16
Free Cash Flow per Basic Share
0.27
0.47
0.31
0.32
0.37
0.54
0.65
0.77
0.88
0.93
1.03
1.05
1.12
1.2
1.23
1.3
1.31
Dividend per Share
2.64
2.95
3.24
3.57
4
4.44
4.95
5.49
6.05
6.8
7.45
8.19
9.06
9.98
10.96
12.06
12.98
Book Value per Share
0.79
0.4
0.08
-0.31
0.28
0.83
0.33
-0.26
-1.4
-2.64
-1.95
-1.51
-4.83
-5.01
-6.95
-6.18
-5.63
Tangible Book Value per Share
198
199
200
202
204
205
206
207
204
205
206
206
206
206
206
205
204
Basic Weighted Avg Shares
728
762
828
942
987
1,048
1,154
1,288
1,352
1,482
1,449
1,580
1,853
2,082
2,342
2,618
2,652
Sales/Revenue/Turnover
21.26
22.05
21.98
22.28
23.75
27.04
29.45
31.71
32.94
31.68
32.7
31.97
26.66
27.17
28.18
27.49
28.44
Operating Margin (%)
27
24
25
35
43
38
38
48
57
78
94
98
126
143
167
206
208
Depreciation Expense
109
116
118
134
161
199
237
289
312
369
355
386
312
389
417
444
472
Net Income, GAAP
28.09
27.23
26.1
26.05
24.95
25.1
25.17
25.78
25.25
16.95
22.08
16.7
22.2
20.74
23.88
23.68
23.58
Effective Tax Rate (%)
14.91
15.28
14.3
14.2
16.33
18.97
20.57
22.42
23.1
24.89
24.5
24.43
16.85
18.69
17.79
16.94
17.79
Profit Margin (%)
201
160
88
60
240
320
241
398
209
223
194
224
250
199
562
625
360
Working Capital
97
138
129
197
286
283
294
612
641
937
778
760
1,342
1,353
2,174
2,130
1,757
LT Debt
576
594
661
702
787
870
904
1,027
964
1,199
1,276
1,382
1,546
1,686
1,877
1,920
2,060
Total Equity
16.67
16.71
16.62
16.48
16.45
18.3
20.62
20.16
18.9
19.08
15.85
17.75
13.57
13.14
12.58
12.35
12.83
Return on Invested Capital (%)
18.22
17.26
15.53
15.1
16.02
17.51
18.88
18.75
17.12
16.87
14.49
15.19
10.78
12.06
11.12
10.72
11.16
Return on Capital (%)
21.86
20.94
19.19
19.57
21.01
23.05
24.6
26.78
26.32
28.03
24.26
23.97
17.59
19.89
19.32
18.72
18.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
329
337
610
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
205
204
203
Market Capitalization
11,509
11,497
10,060

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,714
1,678
1,728
Cash, Cash Equivalents & STI
471
429
380
Accounts Receivable, Net
574
570
659
Inventories
505
540
546
Total Current Liabilities
1,044
1,053
1,368
Payables & Accruals
- -
- -
- -
ST Debt
329
337
610
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.5%
8.56%
2.29%
Free Cash Flow
-210.9%
-138.11%
-281.97%
Net Income, GAAP
9.13%
5.56%
6.51%
Sales/Revenue/Turnover
9.71%
12.6%
11.82%
Total Cash Common Dividend
9.38%
4.71%
5.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
608
578
557
598
2,342
2025
680
644
632
662
2,618
2026
713
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.6
- -
- -
- -
2.02
2025
0.61
- -
- -
- -
2.16
2026
0.75
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.23
2025
0.01
- -
- -
- -
1.3
2026
- -
- -
- -
- -
- -
Similar Companies
Decision Diagnostics Corp. (DECN)
Fabino Enterprises Ltd (FABINO.BO)
Vikram Thermo (India) Limited (VIKRAMTH.BO)
Hikal Limited (HIKAL.BO)
POZEN Inc. (POZN)
Stablecoin Development Corp. (SDEV)
Business
Recordati Industria Chimica e Farmaceutica S.p.A. researches, develops, manufactures and markets pharmaceuticals worldwide, operating through Specialty and Primary Care, and Rare Diseases segments. The company offers a broad portfolio of proprietary and licensed products across therapeutic areas including cardiovascular disorders such as hypertension, angina pectoris and cardiac rhythm disorders with flagship brands Zanidip (lercanidipine, a calcium-channel blocker), Avodart/Combodart/Duodart (dutasteride) and Vazkepa (icosapent ethyl); urogenital treatments for benign prostatic hyperplasia and lower urinary tract symptoms; central nervous system therapies including Reaglia for schizophrenia; anti-infectives such as antibiotics, antivirals, Lomexin for gynecological and dermatological infections and Hexaspray throat spray; gastroenterology products; pain management; dermatologicals; obstetrics and gynecology; over-the-counter pharmaceuticals; consumer healthcare and dietary supplements via Natural Point srl including Magnesio Supremo; and rare disease treatments such as Isturisa (pasireotide) for Cushing's syndrome, Cystadrops for cystinosis, Eligard for hormone-dependent prostate cancer, Sylvant for oncology indications, and pipeline candidates REC 0559 for neurotrophic keratitis and REC 0545 for maple syrup urine disease. Founded in 1926 as Laboratorio Farmacologico Reggiano by Giovanni Recordati in Correggio, Italy, and headquartered in Milan following the 1953 headquarters transfer, the company employs around 4,580 people and maintains operations in approximately 150 countries across Europe, Russia, CIS countries, Ukraine, Turkey, North Africa, US, Canada, Mexico, South America, Japan, Australia and other regions through subsidiaries including Recordati Rare Diseases, Casen Recordati, Jaba Recordati, Recordati Ilaç, Opalia Recordati, Italchimici, Recordati AG and others. Recent developments include the October 2024 agreement with Sanofi to acquire global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease, for an upfront US$825 million plus up to US$250 million in milestones, expected to close by year-end and immediately accretive to EBITDA; a license and supply agreement with Amarin to commercialize Vazkepa strengthening its cardiovascular franchise; ongoing expansion of its rare diseases portfolio into endocrinology and oncology; and prior acquisitions such as EUSA Pharma, Tonipharm, Natural Point, Pro Farma AG and Italchimici to bolster specialty, primary care and OTC offerings.

Company News

APIChatGPT

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Presents at 44th Annual J.P.

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) Q3 2025 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q2 2023 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q1 2023 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q4 2022 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2022 Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q2 2022 Results - Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q1 2022 Results - Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q4 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q3 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q2 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q1 2021 Results - Earnings Call Transcript

  • seekingalpha.com

    Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q4 2020 Results - Earnings Call Transcript

  • gurufocus.com

    5 High-Quality Stocks in the Mediterranean